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Introduction
Liver diseases ranked as the 8th most common
cause of death. Autoimmune liver diseases are
chronic liver diseases characterized by similar clini-
cal features to viral and non-autoimmune liver dis-
orders, but with distinct sero-autoimmunologic
properties. The main kinds of autoimmune liver dis-
eases are autoimmune hepatitis (AIH), primary bil-
iary cirrhosis and primary sclerosing cholangitis.
However, secondary autoimmune liver diseases
have been associated with several underlying ill-
ness, i.e. infections, medications, autoimmune dis-
eases and malignancies (the so-called “overlap syn-
dromes”)(1,2).
AIH was one of the first liver diseases which
an effective treatment was developed to and the
benefit demonstrated by randomized controlled tri-
als. Nevertheless, both the diagnosis and the treat-
ment of this disease presented full of challenges.
Clinical spectrum is very wide, ranging from sub-
clinical and non-progressive disease to fulminant,
lethal hepatic failure. Diagnostic criteria, based on
IgG raising, demonstration of characteristic autoan-
tibodies, and histological features of hepatitis, in
the absence of viral disease, are very helpful.
Adequately high steroid doses are the main-
stay of remission induction treatment, while remis-
sion maintenance is best achieved by azathioprine.
Therapeutic alternatives are required in a
small group of patients, who don’t adequately
respond to these drugs or are intolerant to their side
effects. Here we reported the case of a woman
affected with AIH, successfully treated with corti-
costeroids and immunosuppressive drugs(3).
Case report
A 65-years-old sicilian woman was admitted
in November 2010 to our Medical Department,
due to hypertransaminasemia associated with
increased cholestasis indices.
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She also suffered of high blood pressure,
hypercholesterolemia, gastroesophageal reflux
disease (GERD), osteoporosis, and anxious-
depressive syndrome, pharmacologically treated
with benefit. No history of alcohol intake or
other chronic liver diseases risk factors. Few
days before admission, she underwent a routine
serological examination, which pointed-out
hypertransaminasemia (about 30 times reference
values) and increased cholestasis indices (about 3
times reference values of serum gamma-glu-
tamyltransferase, γ-GT, alkaline phosphatase,
and total and direct bilirubin) but no symptom
was refereed. Physical examination revealed only
mild hepatomegaly, and no cutaneous or mucosal
jaundice was detected. Blood samples, performed
during hospital izat ion,  showed increased
transaminases values (ALT 936 IU/L, AST 593
IU/L), as well as cholestasis indices rising (γ-GT
564 U/L, alkaline phosphatase 215 U/L, hyper-
bilirubinemia, especially conjugated fraction)
and hypergammaglobulinemia. Inflammatory
markers (i.e. erythrocyte sedimentation rate, ESR
and C-reactive protein, CRP) were within the ref-
erence limits, except for a slight increase in fer-
ritinemia. Abdominal ultrasonography did not
show any pathological abnormality.
Several serum tests were then performed:
1) serology for major and minor hepatotrop-
ic viruses (hepatitis A virus [HAV], hepatitis B
virus [HBV]), hepatitis C virus [HCV], Epstein
Barr virus [EBV], cytomegalic virus [CMV], her-
per simplex virus [HSV] 1 and 2) which was
proved negative, except for a weak anti-HCV
antibodies positivity, later disproved;
2) serum cryoglobulins determination was
negative;
3) thyroid hormones showed mild abnormal-
ities, with a slight reduction in thyroid stimulat-
ing hormone (TSH) levels, and a mild increase in
free thyroid hormone fractions (about twice), as
subclinical  hyperthyroidism expression.
Abdominal ultrasonography, negative at first,
was repeated after few days, and showed “mild
liver enlargent, with homogenous echotexture
and regular margins, gallbladder with thickened
walls, and slight increase in the common bile
duct diameter (0.7 cm)”. A third abdominal ultra-
sonography, performed some days later, showed
no variations.
Further investigation was upper abdomen
computerized tomography (CT) with contrast, that
pointed out no differences respect to ultrasound
framework. According to differential diagnosis
approach for unknown origin liver diseases, sero-
logical tests for detection of main autoantibodies
were performed, and they were all negative, with
the exception of anti-nuclear antibodies (ANA) and
atypical peri-nuclear antineutrophil cytoplasmic
antibodies (p-ANCA), both positive at high titters.
Nevertheless, she underwent to liver biopsy, which
showed a framework of autoimmune liver disease
(grading 3/3; staging 1/4; histological scoring 3 +1
+1). During hospitalization, patient had no abdomi-
nal or systemic symptoms that could suggest a
liver disease.
According to the histological diagnosis the
patient underwent high dosage parenteral corticos-
teroid therapy, with substantial benefit. She was
then discharged, advising to practice oral corticos-
teroid therapy, with gradual dosage reduction.
After about three months, she was readmitted to
our Department for clinical and laboratory control:
transaminases and cholestasis indexes appeared to
be reduced by at least 1/3 compared to baseline.
After one year of treatment, all aforesaid serologi-
cal parameters reduced so steroid drugs was
administered at maintenance dose (prednisone 7.5
mg/die). 
Discussion
AIH occurs in all races and geographical
areas. As it is a relatively rare disease, only few
epidemiological data are reported in literature.
These suggest a prevalence of at least 1:10,000. In
developed countries, i.e. USA, AIH accounts for
about 20% of all liver transplantations. In Italy, the
main agent associated with chronic hepatitis is
hepatitis C virus, whereas AIH is almost rare
(prevalence of 0.9% in a survey of 2610 chronic
hepatitis patients), and affects about 50.000-
100.000 individuals. There are no data about
prevalence of autoimmune liver diseases in Sicily,
even though there are some reports about the pres-
ence of AIH in our geographic area(4,5).
Although women are still more affected than
men, lately the percentage of the latter had recently
increased, compared with that in previous studies.
AIH onset age varies greatly, from as early as the
first year of life up until the eighties. However, as
in many other autoimmune diseases, both the
median and the mean age of initial disease mani-
festation are in the forties.
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According to previous data, AIH should be
considered in the differential diagnosis of any
patient with laboratory evidence of liver disease(6).
AIH carries all features of an autoimmune dis-
ease: genetic predisposition, association with other
autoimmune diseases (i.e. Hashimoto thyroiditis,
type 1 diabetes mellitus, celiac disease, systemic
lupus erythematosus, and idiopathic thrombocy-
topenic purpura), spontaneous disease activity fluc-
tuations, autoantibodies, autoreactive T-cells and
inflammatory infiltrate evidence, and a good
response to steroids and immunosuppression. As in
other autoimmune diseases, neither the aetiology of
the disease, nor the triggering factors, nor those that
may lead, in some patients, to spontaneous remis-
sions are known. A genetic predisposition can be
presumed, according to HLA association. Various
other genetic associations have been described (i.e.
genetic polymorphisms of immune response genes),
but most of these have only been studied in rela-
tively small groups of patients, and often have not
been confirmed by other studies(7).
The clinical manifestations of AIH are highly
variable. Almost a third of the patients come to
physician attention with an acute icteric hepatitis,
occasionally even with fulminant, lethal hepatic
failure. However most of the patients have milder
and, some, even subclinical disease. They present
with non-specific symptoms, such as generalized
fatigue. At least a third of patients have already cir-
rhosis at onset of clinical presentation, suggesting
that the disease may be unrecognized for a consid-
erable period of time prior to diagnosis. However,
the frequency of patients with jaundice and/or liver
cirrhosis, at first physician examination, is finally
decreased compared with previous reports one.
A characteristic feature in many patients is an
acute relapsing course. As a matter of fact, most of
them, if not diagnosed or not treated for any other
reason, will experience a spontaneous partial
recovery, and, sometimes even a complete normal-
ization of liver function tests. However, histologi-
cal disease activity usually persists, and another
acute exacerbation is usually predictable within
few months.
Some others progress to a chronic hepatitis,
generally characterized by a fluctuating course. On
clinical examination, signs of chronic liver disease
may be highlighted, i.e. palmar erythema (which
may disappear after successful immunosuppressive
therapy), and palpable enlarged liver, sometimes
swollen and tender. In advanced disease, nodularity
may be palpable(8). Several patients with AIH pre-
sent, late, with cirrhosis, at times decompensated.
Many of them are diagnosed as having a ‘‘crypto-
genic cirrhosis’’, and in the past AIH was the most
common cause of cryptogenic cirrhosis(9).
In 1993 the International Autoimmune
Hepatitis Group developed a scoring system to help
standardization of patients in scientific publica-
tions(10). This scoring system, revised in 1999, has
also been applied by some to daily clinical practice,
for which it had not been primarily designed nor
tested, and found to be very cumbersome(11). In 2008
the International Autoimmune Hepatitis Group sug-
gested a simplified scoring system for clinical prac-
tice, which is useful in most cases(12).
However, diagnosis is based on four features:
hypergammaglobulinaemia, autoantibodies, histol-
ogy and absence of viral hepatitis.
Hypergammaglobulinaemia is the cheapest of these
screening tests, the most characteristic finding
being a selective elevation of serum IgG, with
serum IgA and IgM normal levels. Autoantibodies
are an hallmark of AIH and constitute an important
part of the diagnostic work-up. However, both
ANA and smooth-muscle antibodies (SMA) are not
disease-specific markers. Antibodies versus liver-
kidney microsomes type 1 (LKM1) and atypical p-
ANCA are not disease-specific markers too, and
occur in only a small fraction of patients.
Only SLA/LP autoantibodies are disease-spe-
cific markers, and therefore of high diagnostic
value, but can only be detected by commercial
assays in up to 30% of AIH patients.
Moreover, several studies reported that patients
with AIH and histological features of acute hepatitis
show lower levels of serum IgG and ANA titers.
Histology is considered a necessary prerequisite to
AIH diagnosis. The revised scoring system distin-
guishes ‘‘compatible with AIH’’ histology, scoring as
1 point, from ‘‘typical for AIH’’ histology, scoring as
2 points. Characteristic histological features suggest-
ing typical AIH include interface hepatitis, portal and
periportal inflammation, presence of plasma cells,
resetting of hepatocytes, and emperipolesis. Most
patients with AIH just exhibit complications of
chronic inflammation, including fibrosis, and about a
third of them are already cirrhotic. Cirrhosis in AIH
is often irregular and characterized by macronodular
regeneration. Absence of viral hepatitis was general-
ly thought to be a prerequisite to diagnose AIH, but
in a few patients viral infection and AIH may co-
exist.
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This is particularly relevant in countries with
viral hepatitis high prevalence, where AIH diagno-
sis may be entirely overlooked in viral hepatitis
infected patients. As a matter of fact, autoimmune
phenomena are frequently found in HCV-infected
patients. ANA-positive and HCV infected patients
generally have a lower probability of AIH diagno-
sis. The revised simplified scoring system allows
AIH diagnosis in these patients, proving high IgG
levels and autoantibodies titres, as well as typical
histology, which should be reviewed by an expert
liver histopathologist(13,14,15).
Randomized trials unequivocally showed the
survival benefit of corticosteroid and immunosup-
pressant treatment in patients with AIH. The lately
published American Association for the Study of
Liver Diseases (AASLD) practice guidelines rec-
ommend either an onset dose of 30 mg prednisone
combined with 1-2 mg azathioprine (AZA) per day,
or monotherapy with prednisone at a daily starting
dose of 40-60 mg, in adults.
However, as AZA is hepatotoxic, particularly
in jaundiced patients with decompensated disease,
it is advisable to treat first with steroids high
dosages, then add AZA later, just after jaundice has
subsided and partial disease control is achieved. It
seems that steroids are the mainstay of remission
induction treatment, while remission maintenance
is best achieved by AZA.
The most reasonable approach is probably to
tailor treatment according to the individual patient
characteristics, depending on whether the risk of
steroid side-effects is higher than the risk of long-
term higher azathioprine doses ones, or vice
versa(16). Budesonide is lately receiving considerable
attention as an alternative to prednisone in the treat-
ment of AIH, especially in patients in whom steroid
side-effects are expected to be a problem(17).
With respect to treatment with ursodeoxy-
cholic acid (UDCA), the number of AIH patients
treated with UDCA recently increased compared
with that in previous studies. Although the exact
UDCA underlying activity mechanisms in AIH
have not been clarified, the drug is currently admin-
istered to patients affected with “problematic” AIH,
in addition to steroids and immunosuppressive
drugs(18). 
AIH management requires careful follow-up
and strict adherence to treatment both by treating
physicians and patients. Follow-up biopsies may be
particularly helpful in these patients, to guide
immunosuppressive therapy(19).
Treatment failure occurs in 20% of AIH
patients assuming prednisone and AZA. Few
patients show an insufficient response to standard
immunosuppression, and some show reactivation
during reduction of steroid doses In these patients
stronger immunosuppressive agents appear to be
required, and good results have been reported
administering cyclosporine, tacrolimus, cyclophos-
phamide, infliximab and mycophenolate mofetil.
Specific studies on second line treatment, in
not responsive patients, are needed, and no compar-
ative data are still available(20). It appears that the
calcineurin inhibitors, cyclosporine and tacrolimus,
are efficient agents, but, like in other autoimmune
diseases, they are not immunomodulatory, and
therefore tend to require permanent treatment,
while real immunomodulatory agents, such as
cyclophosphamide or infliximab, may allow reduc-
tion of immunosuppression over time(21).
The TH1/TH2 cytokines production imbalance
has been associated with AIH pathogenesis, and
researchers reported that TH1 cytokines, as TNF-α,
seem to prevail in comparison with TH2 ones in the
liver of patients with active AIH. Therefore, theo-
retically, anti-TNF-α agents (i.e. infliximab) can be
one of the options for AIH treatment; however, a
case of AIH, suspected of resulting from anti-TNF-
α agents, has also been reported. Therefore,
cytokines, as TNF-α, role to the pathogenesis of the
disease may be complex and the efficacy of anti-
TNF-α treatment is still controversial(22).
Treatment with mycophenolate mofetil, salt
form of immunosuppressive drug mycophenolic
acid, induced response or remission in most of
patients with AIH and AZA-intolerance, but it
appears to be of very limited efficacy in patients not
responding to AZA, even if experience in children
is kinder than in adults(23).
Prognosis of treated AIH is usually positive.
Some centers report normal life expectancy rates,
but there may be a patient selection bias. In particu-
lar, some patients with early severe disease progress
rapidly, despite immunosuppression, and require
liver transplantation. Moreover, patients presenting
with already advanced cirrhosis or liver failure may
die in the early phase of treatment, due to infectious
complications related to immunosuppressive drugs.
Liver transplantation is rarely required in patients
affected with AIH, but is more common in children,
who present fulminant hepatitis more often than
adults. Main reasons for liver transplantation are
fulminant disease not enough responding to steroid
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drugs, disease progression due to patient compli-
ance lack, and long-term progression despite ade-
quate treatment, especially in initially already
advanced cirrhosis(24). 
Due to improvement in the prognosis and
aging of AIH patients, malignancies have became
important complications. It was long thought that in
autoimmune liver diseases the risk of hepatocellular
carcinoma (HCC) is negligible. The relative AIH
rarity makes it impossible to correctly evaluate the
incidence of HCC in AIH cirrhosis, but as several
cases of HCC in AIH cirrhosis have been reported
from a variety of centers (about 1.3% of patients
showed HCC during observation period), it appears
reasonable to include AIH cirrhosis among the con-
ditions justifying regular ultrasound screening for
the development of neoplastic foci(25).
In conclusion, our case emphasizes that physi-
cians should always keep in mind the possibility of
AIH in patients who present with features of chron-
ic liver disease, in whom viral studies are negative,
and no history of alcohol intake and no obvious eti-
ology is demonstrable. Screening for autoantibody
should be considered in the general workup of such
patients, together with liver histologic examination. 
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